Global Retailer group OYSHO and Swiss apparel technology group X-BIONIC & X-SOCKS design a collection together / OYSHO by X-BIONIC I Once again, Fashion follows function
Tordera, Spain/Wollerau,Switzerland, 21 December 2020 – OYSHO, part of one of the largest retail groups in the world and Swiss apparel technology group X-BIONIC launched an exclusive ski underwear collection, OYSHO by X-BIONIC.
Once again the Swiss think-tank, recent innovation award winner of the “Future made in Switzerland”, is revolutionising the sports industry with another global partnership. Expanding their footprint on the sports apparel market and branching into the fashion industry.
True to its style, X-BIONIC & X-SOCKS once again affirm that fashion follows function. The new collection composed of ski underwear and skisocks feature the patented technologies that have made the Swiss brand, the number 1 technological sports textile company in the world and the most innovative brand for 12 years in a row.
“By integrating our award winning, patented technologies into this collection for OYSHO, the OYSHO by X-BIONIC ski collection, we allow their customers to feel comfortable and to enjoy their winter sports regardless of the climate conditions. A feeling, unlike anything they have experienced before.” said Professor Dr. Bodo Lambertz, Founder of X-BIONIC.
This exclusive, limited-edition collection for OYSHO is only available at OYSHO.COM and at some of the most exclusive flag ship stores of the Spanish group distributed worldwide.
Bilder
Om news aktuell GmbH
X-BIONIC:
Our scientifically proven thermoregulation technology optimizes body core temperature allowing athletes to perform at their absolute best. With over 800 international patent registrations, over 600 awards and more than 1210 medals in international championships including olympics, X-BIONIC is the leader in technical sportswear and has been named the “Most Innovative Brand” twelve years in a row.
Følg pressemeldinger fra news aktuell GmbH
Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra news aktuell GmbH
Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 13:42:00 CET | Press release
Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions
ORTEC expands German healthcare footprint with strategic acquisition of Klages & Partner13.1.2026 09:00:00 CET | Press release
Acquisition adds over 200 healthcare customers and sector-specific workforce management expertise to ORTEC’s portfolio
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
Dr. Stefanie Kesting appointed as CEO of Thyssengas7.1.2026 14:06:26 CET | Press release
Dortmund, 06.01.2026 As of January 1, 2026, Dr. Stefanie Kesting has been appointed as the new Chief Executive Officer (CEO) of Thyssengas GmbH. She succeeds Dr. Thomas Gößmann, who will retire at the end of February 2026 after nearly nine years at the helm of the company. The leadership transition was announced in autumn 2025.
30 Years of European Spas: Nature, Natural Remedies and Climate Health as Europe’s Unique Strength7.1.2026 08:59:31 CET | Press release
To mark its 30th anniversary, the European Spas Association (ESPA) has released a special commemorative publication highlighting the strategic role of Europe’s medical spas and climate-health resorts in an era defined by prevention, longevity and sustainable wellbeing.
I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.
Besøk vårt presserom